Supernus Pharmaceuticals Inc (NASDAQ:SUPN)’s share price fell 5.6% on Friday . The company traded as low as $35.63 and last traded at $35.66. 772,148 shares traded hands during trading, an increase of 36% from the average session volume of 569,653 shares. The stock had previously closed at $37.79.
A number of research firms have weighed in on SUPN. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research note on Wednesday, March 13th. ValuEngine lowered Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. B. Riley set a $65.00 price objective on Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, March 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Supernus Pharmaceuticals in a research note on Friday, November 23rd. Finally, BidaskClub cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 22nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. Supernus Pharmaceuticals has an average rating of “Hold” and an average target price of $55.75.
The company has a quick ratio of 2.90, a current ratio of 3.06 and a debt-to-equity ratio of 0.73. The stock has a market cap of $1.98 billion, a P/E ratio of 17.40 and a beta of 1.62.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $0.48 EPS for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.19. Supernus Pharmaceuticals had a return on equity of 27.45% and a net margin of 27.14%. The firm had revenue of $113.50 million for the quarter, compared to analysts’ expectations of $105.36 million. During the same period last year, the firm earned $0.26 EPS. The company’s quarterly revenue was up 31.4% on a year-over-year basis. As a group, research analysts forecast that Supernus Pharmaceuticals Inc will post 2.37 EPS for the current year.
In other news, CFO Gregory S. Patrick sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $41.53, for a total transaction of $830,600.00. Following the sale, the chief financial officer now directly owns 67,896 shares in the company, valued at approximately $2,819,720.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.20% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of the company. Meeder Asset Management Inc. boosted its holdings in Supernus Pharmaceuticals by 511.1% in the 4th quarter. Meeder Asset Management Inc. now owns 880 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 736 shares during the last quarter. Advisor Group Inc. boosted its holdings in Supernus Pharmaceuticals by 17.2% in the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 306 shares during the last quarter. Cutler Group LP acquired a new stake in Supernus Pharmaceuticals in the 4th quarter worth about $89,000. Quantbot Technologies LP acquired a new stake in Supernus Pharmaceuticals in the 3rd quarter worth about $113,000. Finally, Laurion Capital Management LP acquired a new stake in Supernus Pharmaceuticals in the 3rd quarter worth about $207,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Supernus Pharmaceuticals (SUPN) Shares Down 5.6%” was first posted by Zolmax and is the sole property of of Zolmax. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://zolmax.com/investing/supernus-pharmaceuticals-supn-shares-down-5-6/2983590.html.
About Supernus Pharmaceuticals (NASDAQ:SUPN)
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Read More: The basics of gap trading strategies
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.